Increased expression of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ in human atherosclerosis

Pathology Research and Practice

Volumn 206, Issue 7, 2010, Pages 429-438

  Sueyoshi, Sumihisa ^a,b   Mitsumata, Masako ^a   Kusumi, Yoshiaki ^a   Niihashi, Mari ^a   Esumi, Mariko ^a   Yamada, Tsutomu ^a   Sakurai, Isamu ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYORIN PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Atherosclerosis; Cell proliferation; Human aorta; Macrophages; PPAR and PPAR

Indexed keywords

CD68 ANTIGEN; KI 67 ANTIGEN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ADOLESCENT; ADULT; AGED; AORTA; ARTERY ENDOTHELIUM; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL AGGREGATION; CELL DENSITY; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FOAM CELL; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MONOCYTE; MONONUCLEAR CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; WESTERN BLOTTING; BIOSYNTHESIS; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AORTA; ATHEROSCLEROSIS; BLOTTING, WESTERN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MIDDLE AGED; MYOCYTES, SMOOTH MUSCLE; PPAR ALPHA; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 77954030199     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2010.01.010     Document Type: Article

References (33)

1. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 1999, 340:115-126.
2. Chawla A., Repa J., Evans R., Mangelsdorf D. Nuclear receptors and lipid physiology: opening the X-files. Science 2001, 294:1866-1870.
3. Barbier O., Torra I.P., Duguay Y., Blanquart C., Fruchart J.C., Glineur C., Staels B. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2002, 22:717-726.
4. Gizard F., Amant C., Barbier O., Bellosta S., Robillard R., Percevault F., Sevestre H., Krimpenfort P., Corsini A., Rochette J., Glineur C., Fruchart J.C., Torpier G., Staels B. PPARalpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16. J. Clin. Invest. 2005, 115:3228-3238.
5. Wakino S., Kintscher U., Kim S., Yin F., Hsueh W.A., Law R.E. Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1--> S transition in vascular smooth muscle cells. J. Biol. Chem. 2000, 275:22435-22441.
6. Zandbergen F., Mandard S., Escher P., Tan N.S., Patsouris D., Jatkoe T., Rojas-Caro S., Madore S., Wahli W., Tafuri S., Muller M., Kersten S. The G0/G1 switch gene 2 is a novel PPAR target gene. Biochem. J. 2005, 392:313-324.
7. Li A.C., Palinski W. Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis. Annu. Rev. Pharmacol. Toxicol. 2006, 46:1-39.
8. Israelian-Konaraki Z., Reaven P.D. Peroxisome proliferator-activated receptor-alpha and atherosclerosis: from basic mechanisms to clinical implications. Cardiology 2005, 103:1-9.
9. Takano H., Hasegawa H., Zou Y., Komuro I. Pleiotropic actions of PPARgamma activators thiazolidinediones in cardiovascular diseases. Curr. Pharm. Des. 2004, 10:2779-2786.
10. Chawla A., Boisvert W.A., Lee C.H., Laffitte B.A., Barak Y., Joseph S.B., Liao D., Nagy L., Edwards P.A., Curtiss L.K., Evans R.M., Tontonoz P. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell 2001, 7:161-171.
11. Chinetti G., Lestavel S., Bocher V., Remaley A.T., Neve B., Torra I.P., Teissier E., Minnich A., Jaye M., Duverger N., Brewer H.B., Fruchart J.C., Clavey V., Staels B. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 2001, 7:53-58.
12. Li A.C., Binder C.J., Gutierrez A., Brown K.K., Plotkin C.R., Pattison J.W., Valledor A.F., Davis R.A., Willson T.M., Witztum J.L., Palinski W., Glass C.K. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J. Clin. Invest. 2004, 114:1564-1576.
13. Staels B., Koenig W., Habib A., Merval R., Lebret M., Torra I.P., Delerive P., Fadel A., Chinetti G., Fruchart J.C., Najib J., Maclouf J., Tedgui A. Activation of human aortic smooth muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998, 393:790-793.
14. Ricote M., Huang J., Fajas L., Li A., Welch J., Najib J., Witztum J.L., Auwerx J., Palinski W., Glass C.K. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc. Natl. Acad. Sci. USA 1998, 95:7614-7619.
15. Marx N., Sukhova G., Murphy C., Libby P., Plutzky J. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am. J. Pathol. 1998, 153:17-23.
16. Law R.E., Goetze S., Xi X.P., Jackson S., Kawano Y., Demer L., Fishbein M.C., Meehan W.P., Hsueh W.A. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 2000, 101:1311-1318.
17. Chinetti G., Gbaguidi F.G., Griglio S., Mallat Z., Antonucci M., Poulain P., Chapman J., Fruchart J.C., Tedgui A., Najib-Fruchart J., Staels B. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. Circulation 2000, 101:2411-2417.
18. Sueyoshi S., Yamada T., Niihasi M., Kusumi Y., Oinuma T., Esumi M., Tsuru K., Imai S., Nemoto N., Sakura I., Mitsumata M. Expression of peroxisome proliferator-activated receptor subtypes in human atherosclerosis. Ann. N. Y. Acad. Sci. 2001, 947:429-432.
19. Chomczynski P., Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 1987, 161:156-159.
20. Jemiolo B., Trappe S. Single muscle fiber gene expression in human skeletal muscle: validation of internal control with exercise. Biochem. Biophys. Res. Commun. 2004, 320:1043-1050.
21. Fukuchi M., Watanabe J., Kumagai K., Baba S., Shinozaki T., Miura M., Kagaya Y., Shirato K. Normal and oxidized low density lipoproteins accumulate deep in physiologically thickened intima of human coronary arteries. Lab. Invest. 2002, 82:1437-1447.
22. Nagy L., Tontonoz P., Alvarez J.G., Chen H., Evans R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998, 93:229-240.
23. Upston J.M., Niu X., Brown A.J., Mashima R., Wang H., Senthilmohan R., Kettle A.J., Dean R.T., Stocker R. Disease stage-dependent accumulation of lipid and protein oxidation products in human atherosclerosis. Am. J. Pathol. 2002, 160:701-710.
24. Kumagai T., Matsukawa N., Kaneko Y., Kusumi Y., Mitsumata M., Uchida K. A lipid peroxidation-derived inflammatory mediator: identification of 4-hydroxy-2-nonenal as a potential inducer of cyclooxygenase-2 in macrophages. J. Biol. Chem. 2004, 279:48389-48396.
25. Meuwissen M., van der Wal A.C., Niessen H.W., Koch K.T., de Winter R.J., van der Loos C.M., Rittersma S.Z., Chamuleau S.A., Tijssen J.G., Becker A.E., Piek J.J. Colocalisation of intraplaque C reactive protein, complement, oxidised low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction. J. Clin. Pathol. 2006, 59:196-201.
26. Zahradka P., Wright B., Fuerst M., Yurkova N., Molnar K., Taylor C.G. Peroxisome proliferator-activated receptor alpha and gamma ligands differentially affect smooth muscle cell proliferation and migration. J. Pharmacol. Exp. Ther. 2006, 317:651-659.
27. Venkata N.G., Robinson J.A., Cabot P.J., Davis B., Monteith G.R., Roberts-Thomson S.J. Mono(2-ethylhexyl)phthalate and mono-n-butyl phthalate activation of peroxisome proliferator activated-receptors alpha and gamma in breast. Toxicol. Lett. 2006, 163:224-234.
28. Zhang J., Ge H., Wang C., Guo T.B., He Q., Shao Q., Fan Y. Inhibitory effect of PPAR on the expression of EMMPRIN in macrophages and foam cells. Int. J. Cardiol. 2007, 117:373-380.
29. Sauerberg P., Pettersson I., Jeppesen L., Bury P.S., Mogensen J.P., Wassermann K., Brand C.L., Sturis J., Woldike H.F., Fleckner J., Andersen A.S., Mortensen S.B., Svensson L.A., Rasmussen H.B., Lehmann S.V., Polivka Z., Sindelar K., Panajotova V., Ynddal L., Wulff E.M. Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. J. Med. Chem. 2002, 45:789-804.
30. Ye J.M., Iglesias M.A., Watson D.G., Ellis B., Wood L., Jensen P.B., Sorensen R.V., Larsen P.J., Cooney G.J., Wassermann K., Kraegen E.W. PPARalpha/gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E531-E540.
31. Bergeron R., Yao J., Woods J.W., Zycband E.I., Liu C., Li Z., Adams V., Berger J.P., Zhang B.B., Moller D.E., Doebber T.W. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: a comparison with PPARgamma agonism. Endocrinology 2006, 147:4252-4262.
32. Vakkilainen J., Steiner G., Ansquer J.C., Aubin F., Rattier S., Foucher C., Hamsten A., Taskinen M.R. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003, 107:1733-1737.
33. Minamikawa J., Tanaka S., Yamauchi M., Inoue D., Koshiyama H. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J. Clin. Endocrinol. Metab. 1998, 83:1818-1820.